[go: up one dir, main page]

MX2019005247A - Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos. - Google Patents

Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos.

Info

Publication number
MX2019005247A
MX2019005247A MX2019005247A MX2019005247A MX2019005247A MX 2019005247 A MX2019005247 A MX 2019005247A MX 2019005247 A MX2019005247 A MX 2019005247A MX 2019005247 A MX2019005247 A MX 2019005247A MX 2019005247 A MX2019005247 A MX 2019005247A
Authority
MX
Mexico
Prior art keywords
compounds
dementia
beta
disease
furo
Prior art date
Application number
MX2019005247A
Other languages
English (en)
Inventor
Jacobus Maria Gijsen Henricus
Franciscus Anna Van Brandt Sven
Jan Rita Rombouts Frederik
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019005247A publication Critical patent/MX2019005247A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a inhibidores de la enzima que escinde APP por el sitio beta, los cuales son compuestos 4,4a,5,7-tetrahidro-3H-furo[3,4-b]piridinilicos que tienen la estructura que se muestra en la Formula (I) [ver fórmula (I)] donde los radicales son como se definen en la memoria descriptiva; la invencion tambien se refiere a composiciones farmaceuticas que comprenden tales compuestos, a procesos para preparar tales compuestos y composiciones, y al uso de tales compuestos y composiciones para la prevencion y el tratamiento de trastornos en los que participa la enzima que escinde APP por el sitio beta, tales como la enfermedad de Alzheimer (EA), deterioro cognitivo leve, enfermedad de Alzheimer preclinica, senilidad, demencia, demencia con cuerpos de Lewy, sindrome de Down, demencia asociada con el accidente cerebrovascular, demencia asociada con la enfermedad de Parkinson y demencia asociada con beta-amiloides.
MX2019005247A 2016-11-04 2017-11-03 Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos. MX2019005247A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16197351 2016-11-04
EP17162307 2017-03-22
PCT/EP2017/078200 WO2018083247A1 (en) 2016-11-04 2017-11-03 4,4a,5,7-tetrahydro-3h-furo[3,4-b]pyridinyl compounds

Publications (1)

Publication Number Publication Date
MX2019005247A true MX2019005247A (es) 2019-06-24

Family

ID=60413151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005247A MX2019005247A (es) 2016-11-04 2017-11-03 Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos.

Country Status (10)

Country Link
US (1) US20200062773A1 (es)
EP (1) EP3535271A1 (es)
JP (1) JP2019532992A (es)
KR (1) KR20190075072A (es)
CN (1) CN109890828A (es)
AU (1) AU2017353510A1 (es)
CA (1) CA3039586A1 (es)
MA (1) MA46698A (es)
MX (1) MX2019005247A (es)
WO (1) WO2018083247A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JP2016504998A (ja) * 2012-12-20 2016-02-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｂａｃｅ阻害剤としてのｃ５，ｃ６オキサ環縮合イミノチアジンジオキシド化合物、組成物およびそれらの使用
KR20170095881A (ko) 2014-12-18 2017-08-23 얀센 파마슈티카 엔.브이. 베타―세크레타제의 ２,３,４,５―테트라히드로피리딘―６―아민 및 ３,４―디히드로―２ｈ―피롤―５―아민 화합물 억제제
CN107849056A (zh) * 2015-08-12 2018-03-27 H.隆德贝克有限公司 Bace1抑制剂2‑氨基‑7a‑苯基‑3,4,4a,5,7,7a‑六氢呋喃并[3,4‑b]吡啶

Also Published As

Publication number Publication date
CA3039586A1 (en) 2018-05-11
US20200062773A1 (en) 2020-02-27
MA46698A (fr) 2021-04-07
JP2019532992A (ja) 2019-11-14
WO2018083247A1 (en) 2018-05-11
AU2017353510A1 (en) 2019-05-02
EP3535271A1 (en) 2019-09-11
KR20190075072A (ko) 2019-06-28
CN109890828A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
PH12013501807A1 (en) 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
PH12012502379A1 (en) 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
MX347912B (es) Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8ilaminautiles como inhibidores de beta-secretasa (bace).
PH12013501805A1 (en) 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
PH12012502377A1 (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
PH12013500345A1 (en) 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
MX357383B (es) Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
MY165209A (en) 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
BR112012033291A2 (pt) derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
MX2017008083A (es) Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
MX368326B (es) Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
MX369629B (es) Derivados de 4-a mino-6-fenil-5,6-dihidroimidazo[1,5 a]pirazina como inhibidores de beta-secretasa (bace).
MX366063B (es) Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5-a]pira zina como inhibidores de beta-secretasa (bace).
MX2018003565A (es) Derivados de 2,3,4,5-tetrahidropiridin-6-amina.
MX2019005247A (es) Compuestos 4,4a,5,7-tetrahidro-3h-furo[3,4-b]piridinilicos.
MX2019010653A (es) Inhibidores de beta secretasa.
MX2019010649A (es) Inhibidores de beta secretasa.
MX2019010659A (es) Inhibidores de beta secretasa.
EA201992055A1 (ru) Ингибиторы бета-секретазы